The ASAM State of the Art Course in Addiction Medicine 2018 (19 CME)

image

Overview

This course is designed specifically for physicians and healthcare professionals seeking an advanced level of knowledge about breakthroughs in the field and will include:

  • Presentations focused on scientific advances and emerging evidence in addiction medicine
  • Sessions organized around ten topics that translate into clinically useful knowledge
  • Special addresses by directors of federal agencies including SAMHSA, NIDA, NIAAA
  • Concise presentations delving into understanding, preventing, diagnosing and treating addiction and co-occurring medical and psychiatric disorders

Learning Objectives

Upon completion, participants should be able to:

  1. Identify the latest epidemiology and prescribing guidelines for opioids and treatment approaches for opioid use disorder.
  2. Identify the latest trends in marijuana legislation, policy, testing, synthetic cannabinoids, and implications for practice.
  3. Explain how animal models are being used to develop medications for stimulant use disorders.
  4. Describe the implications of excessive alcohol use in adolescents, young adults, and women of child bearing potential.
  5. Apply suicide screening and interventions to reduce selfharm in substance-dependent populations.
  6. Refer to behavioral therapies and understand how they are being integrated into new technologies.

Target Audience

  • Addiction medicine specialists who are interested in the latest research in the field and its translation to clinical practice
  • Physicians and other healthcare professionals who seek an advanced level of knowledge of addiction medicine
  • Primary care clinicians who manage patients with addiction in their practice
  • Scientists, researchers, public health officials and advocates dedicated to the field of addiction medicine



The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The ASAM CME Committee and Reviewers Disclosure Listing

First Name Commercial Interests Compensation Received For what Role?
Timothy Brennan MD, MPH, FASAM None
Jeffrey DeVido MD Altria/Philip Morris Stock Inheritance
Paul Earley MD, DFASAM Alkermes, Inc; DynamiCare Health, Inc honoraria; Salary Speaker; VP of Medical Affairs 
James Finch MD, DFASAM None

Marc Fishman MD, DFASAM US World Meds; Alkermes consulting fee, travel; honoraria Consultant; Advisory board
David Galbis-Reig MD, DFASAM Ascension Wisconsin All Saints; Abbvie; Hospira; RespireRX Pharmaceuticals; Abbott Pharmaceuticals; Pfizer Bond Stock& Bond in Retirement IRA; Stock Options; Ownership Interests  Owner; Advisory board; PI; Consultant
Adam Gordon, MD, MPH None
Leslie Hayes, MD None
Abigail Herron DO, DFASAM None
Petros Levounis MD, MA, FASAM None
Carla Marienfeld MD None
Ricardo Restrepo MD, MPH, FASAM None
Richard Ries MD, DFASAM None
Edwin Salsitz MD, DFASAM None
Sharon Stancliff MD, FASAM None
Timothy Wiegand MD, FACMT, FAACT None
Erin Zerbo, MD None
ACCME Accredited with Commendation

ACCME Accreditation Statement

The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement

The American Society of Addiction Medicine designates this enduring material for a maximum of 20.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABPM Maintenance of Certification (MOC)

The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 20.5 LLSA credits towards ABPM MOC Part II requirements.

ABAM Transitional Maintenance of Certification (tMOC)

This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 20.5 AMA PRA Category 1 Credit(s)™ for completing this course.

  • Evaluation and Certificate - ASAM State of the Art Course 2018

    Contains 2 Component(s), Medical Credits Offered

    CME Evaluation for the ASAM State of the Art Course 2018

    Complete the course evaluation first and then claim credits. Attendees should claim only the credit commensurate with the extent of their participation in the activity.

  • Session 1: The Opioid Crisis: Current Status and Treatment Responses (2.25 CME)

    Contains 3 Component(s), Medical Credits Offered

    Earn 2.25 AMA PRA Category 1 Credit(s)™ while learning more about the current status and treatment responses to address the opioid crisis, from this conference recording from The ASAM State of the Art Conference, 2018.

    Session 1 examines several topics in the field of opioid-related morbidity and mortality, as well as the treatment of opioid use disorder. Presenters will dive into updates on opioid misuse, overdose epidemiology, and current national trends. This will be followed by an updated review of evidence-based strategies for opioid overdose prevention, and an overview of data that are the basis of current approaches for the investigation of novel kappa-opioid receptor ligands for the treatment of opioid use disorder. Finally, we will close with a review of recent clinical trials examining the efficacy and effectiveness of extended-release (XR) medications for the treatment of opioid use disorder. Richard C. Dart, MD, PhD, Alexander Y. Walley, MD, MSc, FSAM, Eduardo R. Butelman, PhD, and Joshua D. Lee, MD, MSc bring their years of experience and expertise to deliver an exceptional presentation covering the following: Opioid Epidemiology in the Age of Fentanyl, Opioid Overdose Prevention and Management in a Dynamic Opioid Crisis, Targeting the Kappa-Opioid Receptor System for Developing New Pharmacotherapies for Opioid Use Disorder, and Long-Acting Naltrexone and Buprenorphine Formulations: Efficacy Effectiveness and Comparative Effectiveness.

  • Session 2: Cocaine: How the Cellular Basis of its Impact Tells the Story (2 CME)

    Contains 3 Component(s), Medical Credits Offered

    Earn 2 AMA PRA Category 1 Credit(s)™ while learning more about cocaine and how the cellular basis of its impact tells the story, from this conference recording from The ASAM State of the Art Conference, 2018.

    In session 2, you will learn that cocaine is not just for the 80’s stock broker anymore! The subcellular pharmacokinetics make this a particularly difficult substance to treat. We will walk through the advanced neuroscience, the animal models that define our predictive understanding, and the behavioral aspects of both the pathology and treatment. While opioids have captured recent headlines, cocaine and its close cousin methamphetamine have been smoldering in the background. Although we do not have medications with good evidence for treatment, we can predict the withdrawal syndrome and the behaviors that drive utilization. With this knowledge we can build better interventions that are both helpful and reimbursed. 
  • Session 3: Implications of Expanded Cannabis Access (2 CME)

    Contains 3 Component(s), Medical Credits Offered

    Earn 2 AMA PRA Category 1 Credit(s)™ while learning more about the implications of expanded access to cannabis, from this conference recording from The ASAM State of the Art Conference, 2018.

    Session 3 examines several topics in the field of cannabinoids and cannabis access. This will involve presentations on the epidemiology of cannabis use and cannabis use disorder, followed by an update on cannabis decriminalization, legalization, and use of “medical marijuana” and current laws. Then we will dive into routes of administration, detailed information on “synthetic marijuana,” and the use and consequences thereof. The presentations will describe the consequences of expanded marijuana access in terms of adolescent use, traffic accidents, and marijuana testing in the workplace in states with and without legalization as emerging issues.

    Deborah S. Hasin, PhD, D. Faye Caldwell, JD, Ryan G. Vandrey, PhD, and Michael H. Baumann, PhDbring their years of experience and expertise to deliver an exceptional presentation covering the following:  Epidemiology of Cannabis Use and Cannabis Use Disorder, Reefer Madness? Update on Cannabis Laws and "Medical Marijuana", Routes of Marijuana Administration and Testing, and Biological Effects of Synthetic Cannabinoid Drugs Found in the Street Drug Marketplace.

  • Session 4: Cannabis and Coexisting Disorders (1.5 CME)

    Contains 3 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning more about cannabis and coexisting disorders, from this conference recording from The ASAM State of the Art Conference, 2018.

    Session 4 examines several topics in the field of cannabinoids, cannaboid use, and coexisting disorders. As a continuation of cannabis topics, this session will continue with a presentation on advances in pharmacotherapies for cannabis use disorders, the impact and effect of marijuana use on treating other substance use disorders, consequences of expanded marijuana use on opioid usage, and the CBD products. Kevin M. Gray, MD, Dustin C. Lee, PhD, and Rosalie L. Pacula, PhDbring their years of experience and expertise to deliver an exceptional presentation covering the following: Advances with Pharmacotherapies for Cannabis Use Disorder, Impact of Marijuana Use on Treating Other Substance Use Disorders, and The Public Health Impacts of Expanded Cannabis Access.

  • Session 5: Breaking Down Barriers that Block Quality Care (2.25 CME)

    Contains 3 Component(s), Medical Credits Offered

    Earn 2.25 AMA PRA Category 1 Credit(s)™ while learning more about breaking down barriers that block quality care, from this conference recording from The ASAM State of the Art Conference, 2018.

    In Session 5, you will wonder why you are even watching this session. I mean, we have access to treatment on demand, everyone knows the evidence, there is ample funding for treatment, and thank goodness that everyone screens for addiction in their practice. Maybe we would need this session if there was stigma, but everyone agrees that addiction is a chronic brain disorder and are competing for treatment centers to open in their neighborhoods. Really, thank goodness that medical schools and residency programs spend a lot of time training new physicians for the complexity of this disease and how to treat it. Because of this, we have a vibrant, motivated workforce just waiting for the next addiction patient. So, I am not sure what we are going to discuss, but it would be great if we had an audience for our speakers. Anthony Campbell, RPH, DO, CDR, USPHS, R. Corey Waller, MD, MS, FACEP, DFASAM, and Chideha M. Ohouha MD, MPHbring their years of experience and expertise to deliver an exceptional presentation covering the following: The Federal Policy Response to Removing Barriers, If Getting into the US Was Like Getting into Addiction Treatment We Wouldn't Need a Wall, Buprenorphine Prescribing: Getting to Yes, and Audience Discussion with Panelists.

  • Session 6: Alcohol and Opioid Use in Women and Girls: Health Impacts and Treatment (2 CME)

    Contains 3 Component(s), Medical Credits Offered

    Earn 2 AMA PRA Category 1 Credit(s)™ while learning more about alcohol and opioid use in women and girls, from this conference recording from The ASAM State of the Art Conference, 2018.

    In session 6, you will learn that drinking too much alcohol can seriously affect the health of women and girls. Excessive alcohol use increases the risk of certain types of cancers, heart disease, sexually transmitted diseases, unintended pregnancy, and many other health problems. This session will highlight findings from current research on drinking among women and girls. Deborah S. Hasin, PhD, George F. Koob, PhD, Rajita Sinha, PhD, Grace Chang, MD, MPH, Constance M. Weisner, DrPH, LCSW and Mary E. McCaul, PhDbring their years of experience and expertise to deliver an exceptional presentation covering the following: US Trends in Harmful Substance Use Among Women and Girls, Alcohol and the Female Brain, Harmful Effects of Alcohol and Opioid Use in Women and Girls, Health Impacts of Maternal Alcohol Use, Implementation and Outcomes of Screening and Brief Intervention for Women in Primary Care, and Do Women Benefit from Specialty Treatment for Alcohol and Drug Use Disorders?.

  • Session 7: Substance Use in Adolescents and Young Adults (1 CME)

    Contains 3 Component(s), Medical Credits Offered

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning more about substance use in adolescents and young adults, from this conference recording from The ASAM State of the Art Conference, 2018.

    Session 7 covers problematic substance use and binge drinking often begin in adolescence and young adulthood. Treatments for opioid use disorder are developed in adult populations. Whether the efficacy of opioid use disorder treatments seen in adults translates to similar efficacy in adolescent populations is an empirical question that will be explored. Binge drinking in adolescents and young adults occurs at a time of enhanced neural plasticity and may affect the trajectory of brain development. The effects of binge drinking on brain systems will bediscussed and potential approaches to prevent binge drinking will be highlighted. Wilson M. Compton, MD, MPE and George F. Koob, PhDbring their years of experience and expertise to deliver an exceptional presentation covering the following: Opioid Use Disorder in Adolescents and Young Adults and Prevention of Adolescent Binge Drinking: A Neurodevelopmental View.

  • Session 8: What’s New in Non-Pharmacological Treatments (1.5 CME)

    Contains 3 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning more about what is new in non-pharmacological treatments, from this conference recording from The ASAM State of the Art Conference, 2018.

    Session 8 will provide a brief description of three commonly utilized non-pharmacologic treatments for addictions: contingency management, 12-Step and technology-enhanced treatment. For all three interventions, data concerning efficacy, predictors of treatment success, and implementation issues will be presented. New research findings will be discussed. Richard K. Ries, MD, FAPA, DFASAM, Lisa A. Marsch, PhD, and Maxine Stitzer, PhDbring their years of experience and expertise to deliver an exceptional presentation covering the following: Twelve-Step Facilitation for Those in Treatment for Opioid Use Disorder, Digital Technology-Enhanced Approaches to Treatment and Contingency Management in Clinical Practice.

  • Session 9: Overdose, Self-Harm, Suicide, and the Gray Areas in Between (1.5 CME)

    Contains 3 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning more about overdose, self-harm, suicide, and other gray areas in between, from this conference recording from The ASAM State of the Art Conference, 2018.

    During Session 9 you will learn that suicides and fatal drug overdoses are increasing in the US. Moreover, deaths involving drug intoxication are likely underreported, suggesting the problem is worse than the current statistics show. The contribution of the current opioid epidemic to the escalating deaths from overdose will be highlighted and opioid-specific prevention strategies will be discussed. The continuum of self-harm will be considered from both a risk factor and developmental point of view. Assessment of suicide risk and potential intervention strategies to de-escalate risk will be explored. Richard K. Ries, MD, FAPA, DFASAM, Hilary S. Connery, MD, PhD, and Richard K. Ries, MD, FAPA, DFASAMbring their years of experience and expertise to deliver an exceptional presentation covering the following: Overdose Suicide and the Gray Areas in Between, Diagnosis Prevalence and Interventions of Self-Harm in Addiction Patient Populations, and Suicide Screening and Intervention in Individuals with Substance Use Disorders..